Clinical data | |
---|---|
Trade names | Fiblast |
Other names | CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced) |
Routes of administration | Topical ( spray) [1] |
ATC code | |
Identifiers | |
CAS Number | |
PubChem SID | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C764H1201N217O219S6 |
Molar mass | 17122.67 g·mol−1 |
Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers. [2] [3] [1] It is also currently in preregistration for the treatment of periodontitis. [2] [4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4. [5] [6] The drug has been marketed in Japan since June 2001.[ citation needed]
Clinical data | |
---|---|
Trade names | Fiblast |
Other names | CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced) |
Routes of administration | Topical ( spray) [1] |
ATC code | |
Identifiers | |
CAS Number | |
PubChem SID | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C764H1201N217O219S6 |
Molar mass | 17122.67 g·mol−1 |
Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers. [2] [3] [1] It is also currently in preregistration for the treatment of periodontitis. [2] [4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4. [5] [6] The drug has been marketed in Japan since June 2001.[ citation needed]